CISI FIN(06058) appoints Xie Yuti as the director of compliance and risk control.

16/01/2025

GMT Eight

CISI FIN (06058) issues announcement, Guo Jizhi has resigned from the position of Compliance and Risk Director due to personal development reasons, effective from January 16, 2025. Xie Yuti is appointed as the Compliance and Risk Director of the company, effective from January 16, 2025.

Zhejiang Conba Pharmaceutical (600572.SH) has received two drug registration certificates.

WANT WANT CHINA (00151) spent HK$2.2429 million to repurchase 500,000 shares on January 16th.

Contact: contact@gmteight.com

CISI FIN(06058) appoints Xie Yuti as the director of compliance and risk control.

RECOMMEND

On the eve of Trump's return, traders increased their bets on a strong dollar to the highest level since 2019.

Is it time to sell the dollar and buy treasury bonds? Morgan Stanley: There is a high likelihood of the Fed cutting interest rates in March.

The U.S. FTC approves Chevron Corporation's $53 billion acquisition of Hess Corporation. Challenge from Exxon Mobil Corporation remains unresolved.